Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 1/20 | 0.45 |
| ▸ | CTSK | P43235 | 1/20 | 0.45 |
| ▸ | PSEN1 | P49768 | 8/20 | 0.45 |
| ▸ | PSEN2 | P49810 | 8/20 | 0.45 |
| ▸ | APH1B | Q8WW43 | 8/20 | 0.45 |
| ▸ | NCSTN | Q92542 | 8/20 | 0.45 |
| ▸ | APH1A | Q96BI3 | 8/20 | 0.45 |
| ▸ | PSENEN | Q9NZ42 | 8/20 | 0.45 |
| ▸ | CTSD | P07339 | 4/20 | 0.44 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.44 |
| ▸ | AAK1 | Q2M2I8 | 4/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | REN | P00797 | 1/20 | 0.42 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10151192 | 1.00 | CTSS (0.45) | CTSSCTSKPSEN1PSEN2APH1B | |
| SCHEMBL10151208 | 0.88 | PSEN1 (0.50) | CTSSCTSKPSEN1PSEN2APH1B | |
| SCHEMBL345998 | 0.86 | ALDH1A1 (0.49) | CTSSCTSKKLK5AAK1ALDH1A1 | |
| SCHEMBL8239135 | 0.86 | ALDH1A1 (0.49) | CTSSCTSKKLK5AAK1ALDH1A1 | |
| SCHEMBL8240522 | 0.85 | PPARA (0.53) | CTSSCTSKPSEN1PSEN2APH1B | |
| SCHEMBL345468 | 0.81 | ITGB3 (0.54) | CTSSCTSKAAK1ALDH1A1MAPT | |
| SCHEMBL8239145 | 0.81 | ITGB3 (0.54) | CTSSCTSKAAK1ALDH1A1MAPT | |
| SCHEMBL21529047 | 0.78 | CA1 (0.51) | CTSSCTSKAAK1ALDH1A1MAPT | |
| SCHEMBL21529048 | 0.78 | CA1 (0.51) | CTSSCTSKAAK1ALDH1A1MAPT | |
| SCHEMBL13033014 | 0.78 | AAK1 (0.50) | CTSSCTSKAAK1ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8338471-B2 | (2,5-dioxoimidazolidin-i-yl)-n-hydroxy-acetamides as metalloproteinase inhibitors | MEDIVIR AB (SE) | 2012-12-25 | — | — | US | disclosed |
| US-20120015994-A1 | (2,5-DIOXOIMIDAZOLIDIN-I-YL)-N-HYDROXY-ACETAMIDES AS METALLOPROTEINASE INHIBITORS | MEDIVIR AB (SE) | 2012-01-19 | — | — | US | disclosed |
| US-8022092-B2 | (2,5-dioxoimidazolidin-1-yl)-N-hydroxy-acetamides as metalloproteinase inhibitors | MEDIVIR AB (SE) | 2011-09-20 | — | — | US | disclosed |
| US-20090215846-A1 | (2,5-DIOXOIMIDAZOLIDIN-I-YL)-N-HYDROXY-ACETAMIDES AS METALLOPROTEINASE INHIBITORS | MEDIVIR AB (SE) | 2009-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120015994-A1 | (2,5-DIOXOIMIDAZOLIDIN-I-YL)-N-HYDROXY-ACETAMIDES AS METALLOPROTEINASE INHIBITORS | MMP12, MMP13, MMP14 | CTSS 186/4885CTSK 417/4885PSEN1 3046/4885 |
| US-20090215846-A1 | (2,5-DIOXOIMIDAZOLIDIN-I-YL)-N-HYDROXY-ACETAMIDES AS METALLOPROTEINASE INHIBITORS | MMP12, MMP13, MMP14 | CTSS 186/4885CTSK 417/4885PSEN1 3046/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.